Skip to main content

Table 1 Baseline characteristics of incident SCLC cases

From: Feasibility and validity of The Health Improvement Network database of primary care electronic health records to identify and characterise patients with small cell lung cancer in the United Kingdom

Baseline characteristic Incident SCLC cases (N = 2938)
Sex n %
 Male 1524 51.9
 Female 1414 48.1
Age (years)
 Mean (±SD) 68.45 (68.10–68.80)
 50–59 94 3.2
 60–69 451 15.4
 70–79 972 33.1
 80–89 1054 35.9
Smokinga
 Non-smoker 141 4.8
 Current 1455 49.5
 Former 1299 44.2
 Unknown 43 1.5
BMI (kg/m2)a
 15–19 189 6.4
 20–24 945 32.2
 25–29 926 31.5
 ≥30 590 20.1
 Unknown 288 9.8
Alcohol (units/week)a
 None 18,790 16.5
 1–9 47,121 41.4
 10–20 14,390 12.6
 21–41 4986 4.4
 ≥42 1820 1.6
 Unknown 26,833 23.6
Geographical setting
 Urban 1923 65.5
 Town 303 10.3
 Rural 113 3.8
 Unknown 599 20.4
Comorbiditiesb
 MI 285 9.7
 IS 153 5.2
 PAD 289 9.8
 Heart failure 152 5.2
 Hypertension 1256 42.8
 Hyperlipidaemia 646 22.0
 Dyspepsia 789 26.9
 Depression 847 28.8
 GERD 531 18.1
 Asthma 718 24.4
 COPD 739 25.2
Medicationsc
 Beta2-agonists 1181 40.2
 Oral corticosteroids 849 28.9
 Inhaled steroids 624 21.2
 Antiplatelets 1097 37.3
 NSAIDs 810 27.6
 Opioids 1604 54.6
 PPIs 1125 38.3
 H2RA 232 7.9
  1. aEver before SCLC diagnosis using the most recent value/status as appropriate
  2. bEver before SCLC diagnosis
  3. cIn the year prior to SCLC diagnosis
  4. BMI body mass index, COPD chronic obstructive pulmonary disease, DVT deep vein thrombosis, GERD gastro-oesophageal reflux disease, H2RA histamine 2 receptor antagonists, IS ischaemic stroke, MI myocardial infarction, NSAID non-steroidal anti-inflammatory drug, PAD peripheral artery disease, PPI proton pump inhibitor, SCLC small-cell lung cancer, SD standard deviation, TIA transient ischaemic attack